A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide

Maurizio Mascarin, Stefano Dall'Oglio, Mario Palazzi, Giovanna Sartor, Pier Luigi Marradi, Mario Romano, Sergio Maluta

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We report a case of relapsed high-risk non-metastatic medulloblastoma in a 14-year-old boy, which was treated with intensity-modulated radiotherapy (IMRT) and temozolomide (TMZ). At the age of 11, the patient underwent an MRI-confirmed incomplete resection of a fourth-ventricle medulloblastoma, followed by conventional chemotherapy, craniospinal irradiation (55.8 Gy, 1.8 Gy/fraction) and then myeloablative chemotherapy followed by peripheral blood progenitor cell rescue. After 18 months of complete remission following the completion of chemotherapy, MRI showed a 2.5-cmmass in the olfactory notch. The patient underwent IMRT (45 Gy, 1.8 Gy/fraction) with concomitant administration of TMZ (180 mg/m 2, 5 days every 21 days), which was well tolerated. After 5 cycles of TMZ, MRI showed complete remission with no evidence of the mass. TMZ was continued for another 5 cycles and then stopped. At 14 months from the completion of IMRT, a new MRI scan showed multiple nodular relapses around the fourth ventricle and the patient is currently treated with oral etoposide.

Original languageEnglish
Pages (from-to)327-331
Number of pages5
JournalTumori
Volume96
Issue number2
Publication statusPublished - Mar 2010

Fingerprint

temozolomide
Intensity-Modulated Radiotherapy
Medulloblastoma
Fourth Ventricle
Drug Therapy
Craniospinal Irradiation
Etoposide
Blood Cells
Stem Cells
Magnetic Resonance Imaging
Recurrence

Keywords

  • High-risk medulloblastoma
  • IMRT
  • Relapse
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mascarin, M., Dall'Oglio, S., Palazzi, M., Sartor, G., Marradi, P. L., Romano, M., & Maluta, S. (2010). A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide. Tumori, 96(2), 327-331.

A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide. / Mascarin, Maurizio; Dall'Oglio, Stefano; Palazzi, Mario; Sartor, Giovanna; Marradi, Pier Luigi; Romano, Mario; Maluta, Sergio.

In: Tumori, Vol. 96, No. 2, 03.2010, p. 327-331.

Research output: Contribution to journalArticle

Mascarin, M, Dall'Oglio, S, Palazzi, M, Sartor, G, Marradi, PL, Romano, M & Maluta, S 2010, 'A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide', Tumori, vol. 96, no. 2, pp. 327-331.
Mascarin M, Dall'Oglio S, Palazzi M, Sartor G, Marradi PL, Romano M et al. A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide. Tumori. 2010 Mar;96(2):327-331.
Mascarin, Maurizio ; Dall'Oglio, Stefano ; Palazzi, Mario ; Sartor, Giovanna ; Marradi, Pier Luigi ; Romano, Mario ; Maluta, Sergio. / A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide. In: Tumori. 2010 ; Vol. 96, No. 2. pp. 327-331.
@article{d8230318122349b98631e7213154ebe6,
title = "A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide",
abstract = "We report a case of relapsed high-risk non-metastatic medulloblastoma in a 14-year-old boy, which was treated with intensity-modulated radiotherapy (IMRT) and temozolomide (TMZ). At the age of 11, the patient underwent an MRI-confirmed incomplete resection of a fourth-ventricle medulloblastoma, followed by conventional chemotherapy, craniospinal irradiation (55.8 Gy, 1.8 Gy/fraction) and then myeloablative chemotherapy followed by peripheral blood progenitor cell rescue. After 18 months of complete remission following the completion of chemotherapy, MRI showed a 2.5-cmmass in the olfactory notch. The patient underwent IMRT (45 Gy, 1.8 Gy/fraction) with concomitant administration of TMZ (180 mg/m 2, 5 days every 21 days), which was well tolerated. After 5 cycles of TMZ, MRI showed complete remission with no evidence of the mass. TMZ was continued for another 5 cycles and then stopped. At 14 months from the completion of IMRT, a new MRI scan showed multiple nodular relapses around the fourth ventricle and the patient is currently treated with oral etoposide.",
keywords = "High-risk medulloblastoma, IMRT, Relapse, Temozolomide",
author = "Maurizio Mascarin and Stefano Dall'Oglio and Mario Palazzi and Giovanna Sartor and Marradi, {Pier Luigi} and Mario Romano and Sergio Maluta",
year = "2010",
month = "3",
language = "English",
volume = "96",
pages = "327--331",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide

AU - Mascarin, Maurizio

AU - Dall'Oglio, Stefano

AU - Palazzi, Mario

AU - Sartor, Giovanna

AU - Marradi, Pier Luigi

AU - Romano, Mario

AU - Maluta, Sergio

PY - 2010/3

Y1 - 2010/3

N2 - We report a case of relapsed high-risk non-metastatic medulloblastoma in a 14-year-old boy, which was treated with intensity-modulated radiotherapy (IMRT) and temozolomide (TMZ). At the age of 11, the patient underwent an MRI-confirmed incomplete resection of a fourth-ventricle medulloblastoma, followed by conventional chemotherapy, craniospinal irradiation (55.8 Gy, 1.8 Gy/fraction) and then myeloablative chemotherapy followed by peripheral blood progenitor cell rescue. After 18 months of complete remission following the completion of chemotherapy, MRI showed a 2.5-cmmass in the olfactory notch. The patient underwent IMRT (45 Gy, 1.8 Gy/fraction) with concomitant administration of TMZ (180 mg/m 2, 5 days every 21 days), which was well tolerated. After 5 cycles of TMZ, MRI showed complete remission with no evidence of the mass. TMZ was continued for another 5 cycles and then stopped. At 14 months from the completion of IMRT, a new MRI scan showed multiple nodular relapses around the fourth ventricle and the patient is currently treated with oral etoposide.

AB - We report a case of relapsed high-risk non-metastatic medulloblastoma in a 14-year-old boy, which was treated with intensity-modulated radiotherapy (IMRT) and temozolomide (TMZ). At the age of 11, the patient underwent an MRI-confirmed incomplete resection of a fourth-ventricle medulloblastoma, followed by conventional chemotherapy, craniospinal irradiation (55.8 Gy, 1.8 Gy/fraction) and then myeloablative chemotherapy followed by peripheral blood progenitor cell rescue. After 18 months of complete remission following the completion of chemotherapy, MRI showed a 2.5-cmmass in the olfactory notch. The patient underwent IMRT (45 Gy, 1.8 Gy/fraction) with concomitant administration of TMZ (180 mg/m 2, 5 days every 21 days), which was well tolerated. After 5 cycles of TMZ, MRI showed complete remission with no evidence of the mass. TMZ was continued for another 5 cycles and then stopped. At 14 months from the completion of IMRT, a new MRI scan showed multiple nodular relapses around the fourth ventricle and the patient is currently treated with oral etoposide.

KW - High-risk medulloblastoma

KW - IMRT

KW - Relapse

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=77952924572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952924572&partnerID=8YFLogxK

M3 - Article

C2 - 20572594

AN - SCOPUS:77952924572

VL - 96

SP - 327

EP - 331

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -